CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

XYL-4001

pharmaceutical compound

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionAug 30, 2026
Entity authorityQ132861363 ↗
Source-derived summary

XYL-4001, formerly known as PSYLO-4001, is a non-hallucinogenic serotonin 5-HT2A receptor agonist and psychoplastogen which is under development for the treatment of depressive disorders such as major depressive disorder. Its route of administration is unspecified. The drug is being developed by Xylo Bio (formerly known as Psylo). As of January 2025, it is in the preclinical research stage of development. Its chemical structure does not yet appear to have been disclosed.

Editorial summary

Begin with the source’s own compact description: “XYL-4001” is pharmaceutical compound. The dossier treats that line as a proposition to test through XYL-4001, pharmaceutical and compound, not as a finished interpretation.

Editorial reviewA practical starting point whose main value is the path it opens into stronger specialist and primary sources. The current lead gives the account dated anchors—2025—that can be checked directly. The selected authority fields contribute no independent date. For this dossier, XYL-4001, pharmaceutical and compound is the immediate research focus.
Editorial analysis

Why this record matters

The phrase “pharmaceutical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.

Evidence profile

The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 30, 2026. The linked authority identifier is Q132861363. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2025.

Critical limits

A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “XYL-4001”, its source revision and the description used here.
  2. Expand the search: follow XYL-4001 primary sources, XYL-4001 archive and XYL-4001 research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “XYL-4001”?
  2. Which institution is responsible for the underlying evidence?
  3. Which cited source is closest to the event, object or claim?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “XYL-4001” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.